Wynzora

intended to target inflammatory skin lesions to alleviate psoriasis symptoms.

Strengths: 0.05/0.005%

Medicine details

Therapeutic class

Corticosteroid; Vitamin D analogue

Pharmacological class

Glucocorticoids; Vitamin D3 derivative

Minor side effects

pruritus; skin irritation

Moderate side effects

folliculitis; skin atrophy; pigmentary changes

Dosage forms

Cream

Administration route

Cutaneous use

Patient summary

intended to target inflammatory skin lesions to alleviate psoriasis symptoms.

Prescription status

POM

Manufacturer

LEO Pharma

Onset Time

1–2 weeks

Duration

up to 8 weeks

Storage instructions

Store below 25°C.

Age restrictions

Not for children under 18 years.

Contraindications

calcium metabolism disturbance; viral skin infections; tuberculosis of the skin; hypersensitivity to components

Precautions and warnings

avoid application on the face; limit total weekly dosage; avoid excessive exposure to sunlight

Serious side effects

hypercalcaemia — requires immediate medical attention; cushing's syndrome — requires immediate medical attention

Mechanism of action

Combines a potent corticosteroid for anti-inflammatory effects and a vitamin D analogue to regulate skin cell growth and reduce hyperproliferation.

Pregnancy and breastfeeding

Pregnancy: Use with caution only if benefits outweigh risks. Breastfeeding: Avoid application to the breasts.

Wynzora

intended to target inflammatory skin lesions to alleviate psoriasis symptoms.

Editorial Notes

  • Active ingredient(s): Betamethasone, Calcipotriol
  • Listed indication(s): Plaque Psoriasis

Available option

  • 2 tubes - 0.05/0.005 %1558-0-05-0-005-pct-18097